Anergis Starts European Phase IIb Clinical Trial with AllerT in Patients with Allergy to Birch Pollen
First patient treated with novel allergy vaccine
12-Nov-2012 -
Anergis reported that it has treated the first patient in a large, well-controlled Phase IIb clinical trial in individuals with birch pollen allergy. The trial is designed to evaluate the efficacy and tolerability of a 5-injection / 2- months treatment with Anergis´ lead allergy vaccine, AllerT. ...
allergies
phase IIb studies